Darapladib
Darapladib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against platelet-activating factor acetylhydrolase.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
22 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Atherosclerosis | D050197 | EFO_0003914 | I25.1 | 13 | 4 | 2 | — | — | 19 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | 1 | 1 | — | 1 | 3 |
| Acute coronary syndrome | D054058 | EFO_0005672 | — | — | — | 1 | — | — | 1 |
| Syndrome | D013577 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Coronary disease | D003327 | — | — | — | 1 | — | — | 1 | 2 |
| Coronary artery disease | D003324 | — | I25.1 | — | 1 | — | — | 1 | 2 |
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | 1 | — | — | 1 | 2 |
| Macular edema | D008269 | — | — | — | 1 | — | — | — | 1 |
| Diabetic retinopathy | D003930 | EFO_0003770 | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Asthma | D001249 | EFO_0000270 | J45 | 1 | — | — | — | — | 1 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 1 | — | — | — | — | 1 |
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | 1 | — | — | — | — | 1 |
| Blister | D001768 | — | — | 1 | — | — | — | — | 1 |
| Renal insufficiency | D051437 | HP_0000083 | N19 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Darapladib |
| INN | darapladib |
| Description | Darapladib is an inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2) that is in development as a drug for treatment of atherosclerosis.
|
| Classification | Small molecule |
| Drug class | phospholipase A2 inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCN(CC)CCN(Cc1ccc(-c2ccc(C(F)(F)F)cc2)cc1)C(=O)Cn1c(SCc2ccc(F)cc2)nc(=O)c2c1CCC2 |
Identifiers
| PDB | — |
| CAS-ID | 356057-34-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL204021 |
| ChEBI ID | — |
| PubChem CID | 9939609 |
| DrugBank | — |
| UNII ID | UI1U1MYH09 (ChemIDplus, GSRS) |
Target
Agency Approved
PLA2G7
PLA2G7
Organism
Homo sapiens
Gene name
PLA2G7
Gene synonyms
PAFAH
NCBI Gene ID
Protein name
platelet-activating factor acetylhydrolase
Protein synonyms
1-alkyl-2-acetylglycerophosphocholine esterase, 2-acetyl-1-alkylglycerophosphocholine esterase, Group-VIIA phospholipase A2, gVIIA-PLA2, LDL-associated phospholipase A2, LDL-PLA(2), lipoprotein-associated phospholipase A2, PAF 2-acylhydrolase, PAF acetylhydrolase, phospholipase A2, group VII (platelet-activating factor acetylhydrolase, plasma)
Uniprot ID
Mouse ortholog
Pla2g7 (27226)
platelet-activating factor acetylhydrolase (Q921T4)
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 778 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use